查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1928590

勃起功能障碍市场依产品类型、治疗类型、给药途径、年龄层、通路、最终用户划分，全球预测（2026-2032年）

Erectile Dysfunction Market by Product Type, Treatment Type, Route Of Administration, Patient Age Group, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，治疗勃起功能障碍的药物市场价值将达到 131.1 亿美元，到 2026 年将成长到 138.2 亿美元，到 2032 年将达到 181 亿美元，年复合成长率为 4.70%。

关键市场统计数据
基准年 2025 131.1亿美元
预计年份：2026年 138.2亿美元
预测年份 2032 181亿美元
复合年增长率 (%) 4.70%

针对勃起功能障碍的综合框架，重点关注临床创新、通路转型和以患者为中心的转变，这需要策略调整。

勃起功能障碍（ED）是一种具有重要临床意义的疾病，其治疗方法不断发展，患者期望不断变化，竞争也日益激烈。药理学、医疗设备工程和远端医疗等技术的进步正在拓展临床医生诊断和治疗ED的方式，而知情的患者则要求治疗方案便捷、耐受性好，并能改善长期生活品质。在此背景下，相关人员必须应对复杂的监管环境、通路以及快速的技术整合，才能保持竞争力。

临床、数位化和支付方趋势的融合将如何重塑急诊生态系统中的治疗路径和商业策略

勃起功能障碍治疗领域正经历变革性的转变，这主要得益于技术、监管和消费者趋势的融合。首先，治疗创新已不再局限于配方上的渐进式改进，而是扩展到新型给药系统和器械治疗方案的整合，这迫使人们重新评估传统的临床路径。随着临床医师在考虑疗效的同时，也开始关注药物的持久性、併发症情况以及与患者生活方式的契合度，这些进步最终将重塑临床指引和转诊模式。

供应链风险评估和策略采购应对措施，以因应关税对医疗设备组件、药品原料和分销经济造成的成本压力。

近期贸易政策的发展以及可能对医疗进口征收关税，使得治疗勃起功能障碍药物的生产商和供应商更加关注供应链风险。关税会增加医疗设备和某些活性药物原料药的到岸成本，迫使企业重新评估供应商合约、库存管理政策和定价策略。为此，许多企业正在加速采购多元化，评估近岸外包方案，并协商长期供应协议，以降低进口成本波动带来的风险。

一个将治疗方法、产品形式、通路、临床环境、给药途径和年龄层与战术性商业性决策联繫起来的多维细分框架

详细的市场细分框架对于了解勃起功能障碍治疗的患者需求、商业化路径和临床应用至关重要。根据治疗类型，市场可分为口服药物、阴茎植入、阴茎注射剂和真空勃起装置。在口服药物方面，我们将重点放在PDE5抑制剂，并按分子进行详细分析，包括阿伐那非、Sildenafil、他达拉非和伐地那非，从而能够针对每种治疗方案製定差异化的临床和行销策略。依产品类型划分，市场可分为医疗设备和药品，其中医疗设备可分为阴茎植入、阴茎注射剂和真空勃起装置。药品则从PDE5抑制剂及其活性成分的角度进行分析，以阐明研发重点和生命週期管理方法。

监管、报销和生产环境的区域差异是优化打入市场策略和跨境利用证据的关键因素。

区域趋势在塑造勃起功能障碍药物的监管路径、报销环境和患者获取途径方面发挥关键作用。在美洲，成熟的市场、健全的私人保险体系和完善的专业分销基础设施支持新型口服药物和器械技术的快速上市，但也造成了复杂的报销谈判动态。相较之下，欧洲、中东和非洲地区（EMEA）呈现出各国监管环境和支付方环境的复杂性，需要製定量身定制的定价和市场进入策略，尤其对于高成本器材和新型治疗类别而言更是如此。

综合竞争格局分析：揭示现有製药公司、医疗设备创新者和数位新兴企业如何重塑赢得临床医生信任和病人青睐的路径

勃起功能障碍领域的竞争动态呈现出多元化的态势，既有成熟的医疗设备创新企业，也有专注于直接面向消费者的数位参与企业。领先的製药公司在口服製剂领域保持强大的品牌知名度，并持续投资于生命週期管理、新製剂研发和联合治疗研究，以维持其临床疗效。医疗设备公司则透过改进生物相容性材料、小型化技术、提供手术技术支援以及以患者长期疗效为导向的售后服务模式，不断强化自身差异化优势。

为领导者提供切实可行的策略性倡议，透过整合证据和管道多元化，确保临床可信度、营运韧性和商业性规模。

寻求加速成长并维持市场地位的产业领导者应实施一系列切实有效的措施。首先，应优先进行整合证据产生工作，将随机临床数据与可靠的真实世界结果相结合，以支持与支付方的对话并促进临床医生采纳。儘早投资于卫生经济学和生活品质 (QOL) 指标将有助于减少报销摩擦并增强产品差异化。其次，为抵御贸易摩擦对生产的影响，企业应实现供应商和生产能力的多元化，并制定紧急时应对计画，以确保医疗服务的连续性和关键零件的供应。

我们采用稳健的多方法研究途径，整合临床医生访谈、监管审查和商业情报，以确保提供基于证据的策略指导。

本分析的调查方法结合了定性和定量方法，旨在提供严谨且可操作的见解。主要研究包括与临床医生、支付方、采购专业人员和患者权益倡导代表进行结构化访谈和深入讨论，以收集关于治疗选择决定因素、报销障碍和医疗服务限制的真实观点。除了与这些相关人员的对话外，还召开咨询小组会议，以检验假设并发现新兴的临床实践模式。

策略重点的简要概述强调了证据整合、供应链韧性和数位化患者路径，以确保长期领先地位。

总而言之，随着药理学、医疗设备技术和数位化医疗模式的创新不断涌现，以及支付方日益严格的审查和不断变化的贸易环境，勃起功能障碍治疗领域正处于战略转折点。成功的相关人员将是那些能够将临床差异化转化为对医疗服务提供者和支付方清晰价值提案，同时建立价值链韧性和通路适应性的企业。不同年龄层、给药途径和分销管道的患者需求之间的相互作用，凸显了製定个人化商业化策略的必要性，这些策略应关注患者的依从性、用药便利性和长期治疗效果。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依产品类型分類的勃起功能障碍市场

  • 装置
    • 阴茎植入
    • 阴茎注射
    • 真空勃起装置
  • 药物
    • 阿伐那菲尔
    • Sildenafil
    • 他达拉非

第九章 依治疗方法的勃起功能障碍市场

  • 口服药物
  • 阴茎植入
  • 阴茎注射
  • 真空勃起装置

第十章 依给药途径分類的勃起功能障碍市场

  • 注射
  • 口服
  • 外用药物

第十一章 依患者年龄层分類的勃起功能障碍市场

  • 40-49岁
  • 50-59岁
  • 60-69岁
  • 70岁或以上

第十二章 按分销管道分類的勃起功能障碍市场

  • 诊所药房
  • 医院药房
  • 网路药房
  • 零售药房

第十三章 依最终用户分類的勃起功能障碍市场

  • 诊所
  • 居家医疗
  • 医院

第十四章 各地区勃起功能障碍市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 按群体分類的勃起功能障碍市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国勃起功能障碍市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国勃起功能障碍市场

第十八章 中国勃起功能障碍市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bayer AG
  • Boston Scientific Corporation
  • Cipla Limited
  • Coloplast Group
  • Dong A Socio Holdings Co. Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Endo International Plc
  • Futura Medical Plc
  • GlaxoSmithKline plc
  • Lupin Limited
  • Pfizer Inc.
  • Sandoz International GmbH
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Vivus, Inc.
Product Code: MRR-92740D85F052

The Erectile Dysfunction Market was valued at USD 13.11 billion in 2025 and is projected to grow to USD 13.82 billion in 2026, with a CAGR of 4.70%, reaching USD 18.10 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 13.11 billion
Estimated Year [2026] USD 13.82 billion
Forecast Year [2032] USD 18.10 billion
CAGR (%) 4.70%

Comprehensive framing of the erectile dysfunction landscape highlighting clinical innovation, channel disruption, and patient-centered shifts that demand strategic recalibration

Erectile dysfunction (ED) remains a clinically significant condition with evolving therapeutic options, shifting patient expectations, and intensifying commercial competition. Advances in pharmacology, device engineering, and telehealth-enabled care pathways have expanded how clinicians diagnose and manage ED, while an increasingly informed patient population seeks treatments that align with convenience, tolerability, and long-term quality of life. Against this backdrop, industry stakeholders must navigate regulatory complexity, channel fragmentation, and rapid technological convergence to remain relevant.

Recent years have seen an acceleration of innovation across oral agents, implantable devices, and minimally invasive therapies, which has reshaped clinical decision algorithms and payer conversations. Simultaneously, the rise of digital health platforms and online pharmacies has altered patient acquisition dynamics, bringing new entrants into the care continuum and challenging incumbent distribution models. As a result, manufacturers and service providers must re-evaluate product positioning, evidence generation strategies, and engagement models to meet both clinical and commercial objectives.

This introductory synthesis frames the remainder of the executive summary by outlining the systemic drivers reshaping the ED landscape. It highlights the interplay between clinical innovation, channel evolution, regulatory scrutiny, and patient centricity to set a strategic lens for stakeholders pursuing sustainable differentiation in a complex market environment.

How converging clinical, digital, and payer dynamics are reshaping therapeutic pathways and commercial strategies across the erectile dysfunction ecosystem

The landscape for erectile dysfunction treatment is experiencing transformative shifts driven by converging technological, regulatory, and consumer trends. First, therapeutic innovation has moved beyond incremental formulation changes to integrate novel delivery systems and device-based options, forcing a reappraisal of long-standing clinical pathways. These advances are prompting clinicians to weigh efficacy alongside durability, complication profiles, and patient lifestyle alignment, ultimately reshaping clinical guidelines and referral patterns.

Second, digital health and telemedicine have accelerated access to care and altered patient journeys, enabling discreet, rapid initiation of treatment while introducing new channels for ongoing monitoring and adherence support. Third, payer scrutiny and value-based contracting are increasingly influencing formulary positioning and device reimbursement, which drives manufacturers to invest in real-world evidence and health economics outcomes research. Fourth, supply chain resilience and manufacturing flexibility have gained prominence, encouraging strategic supplier diversification and localized sourcing where feasible.

Collectively, these shifts create both risk and opportunity: established players must adapt their commercialization playbooks, while agile entrants can leverage digital-first models and targeted clinical differentiation to capture underserved segments. The net result is an industry at an inflection point where integrated strategies across R&D, regulatory, and commercial functions are essential to capture long-term value.

Assessing supply chain exposure and strategic procurement responses to tariff-driven cost pressures that affect device components, drug ingredients, and distribution economics

Recent trade policy developments and the potential introduction of tariffs affecting medical imports have heightened scrutiny of supply chain exposure for manufacturers and suppliers of erectile dysfunction treatments. Tariffs can increase landed costs for devices and certain active pharmaceutical ingredients, prompting firms to reassess supplier contracts, inventory policies, and pricing strategies. In response, many organizations have accelerated procurement diversification, evaluated nearshoring options, and negotiated long-term supplier agreements to mitigate exposure to import cost volatility.

The cumulative operational impacts extend to manufacturing planning and inventory holding patterns. Companies reliant on specialized components for penile implants or device assemblies may encounter longer lead times and the need for qualified secondary suppliers, which in turn can influence time-to-patient and aftermarket support capabilities. For drug manufacturers and distributors, tariff-related cost pressures can affect wholesale pricing negotiations and channel margin structures, particularly in channels with high price sensitivity such as online and retail pharmacies.

Regulatory and compliance teams are also revisiting tariff-driven changes to customs classification and documentation requirements, while commercial teams explore reimbursement conversations informed by incremental cost structures. Importantly, firms are prioritizing scenario planning and cost pass-through analyses, while seeking to protect patient access by maintaining continuity of supply and preserving clinically appropriate treatment options despite potential trade headwinds.

A multi-dimensional segmentation framework tying treatment modality, product form, distribution route, care setting, administration route, and age cohorts to tactical commercial decisions

A nuanced segmentation framework is essential to understand patient need, commercialization pathways, and clinical adoption for erectile dysfunction treatments. Based on Treatment Type, the market is studied across oral agents, penile implants, penile injections, and vacuum erection devices; within oral agents the focus narrows to PDE5 inhibitors, which are further examined by molecule, including avanafil, sildenafil, tadalafil, and vardenafil, enabling differentiated clinical and marketing strategies for each therapeutic profile. Based on Product Type, the market is distinguished between devices and drugs, with devices categorized as penile implants, penile injections, and vacuum erection devices, and drugs discussed through the lens of PDE5 inhibitors and their individual active ingredients to clarify development priorities and lifecycle management approaches.

Based on Distribution Channel, the analysis considers clinic pharmacy, hospital pharmacy, online pharmacy, and retail pharmacy pathways to reveal channel-specific access barriers and revenue models. Based on End User, segmentation traces use across clinics, homecare settings, and hospitals to illuminate service delivery models and opportunities for patient education and remote monitoring. Based on Route of Administration, treatments are grouped into injectable, oral, and topical formats to align clinical preference and adherence considerations with commercialization tactics. Finally, based on Patient Age Group, the framework examines cohorts aged 40-49, 50-59, 60-69, and 70-plus to surface age-related prevalence patterns, comorbidity interactions, and tailored engagement approaches. Together, these segmentation lenses provide a comprehensive map for product development, evidence generation, and go-to-market prioritization that aligns with clinical behavior and patient expectations.

Regional differentiation in regulatory, reimbursement, and manufacturing realities that determines tailored market entry strategies and cross-border evidence leverage

Regional dynamics play a pivotal role in shaping regulatory pathways, reimbursement environments, and patient access for erectile dysfunction therapies. In the Americas, market maturity, robust private payer systems, and an established specialty distribution infrastructure support rapid adoption of novel oral agents and device technologies, while also presenting complex reimbursement negotiation dynamics. By contrast, Europe, Middle East & Africa presents a mosaic of national regulatory frameworks and heterogeneous payer landscapes that demand tailored pricing and market-access strategies, especially for high-cost devices or new therapeutic categories.

Asia-Pacific is characterized by fast-growing healthcare investment, diverse regulatory timelines, and a rising prevalence of lifestyle-related comorbidities that influence disease burden and treatment-seeking behavior. Regional manufacturing capabilities and supplier networks also vary significantly across these geographies, which affects sourcing decisions and time to market. Cross-region collaboration and strategic entry sequencing allow companies to leverage early evidence generation in one geography to support regulatory submissions and payer discussions in others, while local partnerships can accelerate market penetration and distribution reach.

Understanding these regional nuances is critical for designing differentiated launch strategies, prioritizing reimbursement dossiers, and aligning clinical evidence generation with the expectations of regulators, payers, and clinicians in each jurisdiction.

Competitive landscape synthesis showing how pharmaceutical incumbents, device innovators, and digital entrants are reshaping pathways to clinician trust and patient preference

Competitive dynamics in the erectile dysfunction space reflect a mix of established pharmaceutical innovators, specialized medical device manufacturers, and digitally native entrants that focus on direct-to-consumer care pathways. Leading pharmaceutical players maintain strong brand recognition for oral agents and continue to invest in lifecycle management, new formulations, and combination therapy research to preserve clinical relevance. Device manufacturers are increasingly differentiating through improvements in biocompatible materials, miniaturization, and surgical technique support, alongside aftermarket service models that emphasize long-term patient outcomes.

New entrants are leveraging telemedicine platforms and subscription-based distribution to acquire patients rapidly, which has altered traditional physician referral patterns and created pressure on channel margins. Partnerships between device firms and specialty clinics are becoming more common to deliver integrated treatment packages that combine procedure capability with ongoing patient management. Additionally, contract research organizations and real-world evidence partners play an expanding role in supporting health economics data generation necessary for formulary and reimbursement discussions.

In this competitive environment, organizations that align clinical differentiation with scalable distribution models and robust evidence-generation plans are best positioned to capture clinician trust and patient preference. Strategic collaborations, targeted investments in post-market surveillance, and clear value communication to payers will continue to separate leaders from followers.

Practical strategic initiatives for leaders to secure clinical credibility, operational resilience, and commercial scale through integrated evidence and channel diversification

Industry leaders seeking to accelerate growth and defend market position should adopt a set of pragmatic, high-impact actions. First, prioritize integrated evidence generation that combines randomized clinical data with robust real-world outcomes to support payer conversations and clinician adoption; investing early in health economics and quality-of-life measures will reduce reimbursement friction and strengthen product differentiation. Second, diversify supplier and manufacturing arrangements to insulate production from trade shocks, and develop contingency plans that preserve continuity of care and spare critical components.

Third, embrace channel diversification by optimizing presence across clinic pharmacy, hospital systems, online pharmacies, and retail outlets, while tailoring pricing and patient-support programs to channel-specific behaviors. Fourth, invest in digital engagement and telehealth integrations that enhance patient acquisition and adherence, enabling personalized care pathways that align with different age cohorts and administration routes. Fifth, pursue strategic alliances with specialty clinics, academic centers, and real-world evidence partners to accelerate adoption and create compelling case studies that illustrate long-term outcomes.

Finally, maintain regulatory agility by monitoring policy shifts and engaging proactively with authorities to clarify classification, reimbursement eligibility, and post-market obligations. Executing these recommendations in a coordinated manner will strengthen resilience, enhance commercial traction, and create defensible advantages in a dynamic competitive landscape.

Robust multi-method research approach integrating clinician interviews, regulatory review, and commercial intelligence to ensure evidence-based strategic guidance

The research methodology underpinning this analysis combines qualitative and quantitative approaches to deliver rigorous, actionable insights. Primary research consists of structured interviews and in-depth discussions with clinicians, payers, procurement specialists, and patient advocacy representatives to capture frontline perspectives on treatment choice drivers, reimbursement barriers, and care delivery constraints. These stakeholder engagements are complemented by advisory panels convened to validate hypotheses and surface emerging clinical practice patterns.

Secondary research includes systematic reviews of peer-reviewed clinical literature, regulatory guidelines, and product registries to ensure that device performance claims and therapeutic efficacy are interpreted within the appropriate scientific context. Commercial intelligence draws upon public filings, patent landscapes, clinical trial registries, and distributor channel mapping to assess competitive positioning and supply chain footprints. Data synthesis involves triangulation across sources, thematic analysis of qualitative insights, and scenario-based sensitivity testing to evaluate strategic options under differing regulatory and trade environments.

This multi-method approach ensures that conclusions reflect both macro-level trends and on-the-ground realities, providing a robust foundation for decision-making by clinical, commercial, and policy stakeholders.

Concise synthesis of strategic priorities emphasizing evidence integration, supply resilience, and digitally enabled patient pathways to secure long-term leadership

In summary, the erectile dysfunction landscape is at a strategic inflection point defined by innovations in pharmacology, device technologies, and digital care models, set against heightened payer scrutiny and evolving trade dynamics. Successful stakeholders will be those that translate clinical differentiation into clear value propositions for clinicians and payers while simultaneously building supply chain resilience and channel adaptability. The interplay between age-segmented patient needs, administration routes, and distribution channels underscores the need for tailored commercialization strategies that address adherence, convenience, and long-term outcomes.

Looking ahead, organizations that invest in integrated evidence generation, diversified procurement strategies, and digital-enabled patient engagement will be better positioned to navigate regulatory complexity and changing reimbursement norms. Cross-functional collaboration between R&D, regulatory, and commercial teams will accelerate the translation of innovation into sustained clinical and commercial impact. Ultimately, the path to leadership will require a mix of clinical credibility, operational excellence, and nimble market execution to meet evolving patient expectations and health-system requirements.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Erectile Dysfunction Market, by Product Type

  • 8.1. Device
    • 8.1.1. Penile Implants
    • 8.1.2. Penile Injections
    • 8.1.3. Vacuum Erection Devices
  • 8.2. Drug
    • 8.2.1. Avanafil
    • 8.2.2. Sildenafil
    • 8.2.3. Tadalafil

9. Erectile Dysfunction Market, by Treatment Type

  • 9.1. Oral Agents
  • 9.2. Penile Implants
  • 9.3. Penile Injections
  • 9.4. Vacuum Erection Devices

10. Erectile Dysfunction Market, by Route Of Administration

  • 10.1. Injectable
  • 10.2. Oral
  • 10.3. Topical

11. Erectile Dysfunction Market, by Patient Age Group

  • 11.1. 40-49
  • 11.2. 50-59
  • 11.3. 60-69
  • 11.4. 70+

12. Erectile Dysfunction Market, by Distribution Channel

  • 12.1. Clinic Pharmacy
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Erectile Dysfunction Market, by End User

  • 13.1. Clinics
  • 13.2. Homecare
  • 13.3. Hospitals

14. Erectile Dysfunction Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Erectile Dysfunction Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Erectile Dysfunction Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Erectile Dysfunction Market

18. China Erectile Dysfunction Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Bayer AG
  • 19.6. Boston Scientific Corporation
  • 19.7. Cipla Limited
  • 19.8. Coloplast Group
  • 19.9. Dong A Socio Holdings Co. Ltd.
  • 19.10. Dr. Reddy's Laboratories Ltd.
  • 19.11. Eli Lilly and Company
  • 19.12. Endo International Plc
  • 19.13. Futura Medical Plc
  • 19.14. GlaxoSmithKline plc
  • 19.15. Lupin Limited
  • 19.16. Pfizer Inc.
  • 19.17. Sandoz International GmbH
  • 19.18. Sanofi S.A.
  • 19.19. Sun Pharmaceutical Industries Ltd.
  • 19.20. Teva Pharmaceutical Industries Ltd.
  • 19.21. Viatris Inc.
  • 19.22. Vivus, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ERECTILE DYSFUNCTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ERECTILE DYSFUNCTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY AVANAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY SILDENAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TADALAFIL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PENILE INJECTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY VACUUM ERECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 40-49, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 50-59, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 60-69, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY 70+, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINIC PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOMECARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 152. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 155. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 156. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 165. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 166. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 174. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 175. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. BRICS ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 201. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 202. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 204. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 206. G7 ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 211. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 214. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. NATO ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL ERECTILE DYSFUNCTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. CHINA ERECTILE DYSFUNCTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DEVICE, 2018-2032 (USD MILLION)
  • TABLE 229. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DRUG, 2018-2032 (USD MILLION)
  • TABLE 230. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 232. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 233. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA ERECTILE DYSFUNCTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)